The effects of a Chinese herbal medicine (VGHBPH0) on patients with benign prostatic hyperplasia: A pilot study

Background: The current Western medicine treatment options for benign prostatic hyperplasia (BPH) have various degrees of documented effectiveness. However, the uses of these interventions are limited to specific patient populations or have certain side effects that interfere with patient quality of life. This study evaluated the clinical effects of a Chinese herbal medicine (CHM) on patients with BPH. Methods: This was a single-arm pilot study. Twenty BPH patients were enrolled, and they were required to take the investigated CHM three times a day for 8 weeks, along with their Western medicine. Patients returned to clinics as scheduled and completing international prostate symptoms scores (IPSS), aging male symptoms score, international index of erectile function, and body constitution questionnaire of traditional Chinese medicine. Uroflowmetry and sonography were also applied to evaluate the changes in urinary velocity and post-voiding residual urine volume from the baseline to the end of the study. Results: The mean IPSS total score was significantly decreased by 2.5 points after 8 weeks of treatment with the CHM (from 17.5 to 15.0, p = 0.03). The mean IPSS voiding subscore was decreased by 1.7 points (from 10.1 to 8.4, p = 0.02), and the mean incomplete emptying subscore was decreased by 0.8 points (from 2.9 to 2.1, p = 0.02), with both decreases being statistically significant. A descending trend in the post-voiding residual urine volume was also observed (from 52.9 to 30.8 mL, p = 0.07). Conclusion: This trial indicated that the add-on CHM treatment (VGHBPH0) might be a potential treatment for improving the lower urinary tract symptoms of BPH patients.

[1]  M. Naito,et al.  Gosha-Jinki-Gan Recovers Spermatogenesis in Mice with Busulfan-Induced Aspermatogenesis , 2018, International journal of molecular sciences.

[2]  C. Roehrborn,et al.  Erectile Dysfunction and Lower Urinary Tract Symptoms. , 2017, European urology focus.

[3]  Weiling Li,et al.  Anti-tumor and chemosensitization effects of Cryptotanshinone extracted from Salvia miltiorrhiza Bge. on ovarian cancer cells in vitro. , 2017, Journal of ethnopharmacology.

[4]  Xian-peng Ma,et al.  Qualitative and Quantitative Characterization of Monosaccharide Components of Salvia miltiorrhiza, Liguspyragine Hydrochloride, and Glucose Injection , 2017, Journal of analytical methods in chemistry.

[5]  L. Li,et al.  Salvia miltiorrhiza Roots against Cardiovascular Disease: Consideration of Herb-Drug Interactions , 2017, BioMed research international.

[6]  Yuanyuan Deng,et al.  Icariside II, a Broad-Spectrum Anti-cancer Agent, Reverses Beta-Amyloid-Induced Cognitive Impairment through Reducing Inflammation and Apoptosis in Rats , 2017, Front. Pharmacol..

[7]  Shu-Ying Gao,et al.  The effects of icariin on the expression of HIF-1α, HSP-60 and HSP-70 in PC12 cells suffered from oxygen–glucose deprivation-induced injury , 2017, Pharmaceutical biology.

[8]  Y. Ho,et al.  The Protective Effects of Icariin against the Homocysteine-Induced Neurotoxicity in the Primary Embryonic Cultures of Rat Cortical Neurons , 2016, Molecules.

[9]  P. Paśko,et al.  Interactions between medications employed in treating benign prostatic hyperplasia and food - A short review. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[10]  F. Lowe,et al.  Complementary and alternative medications for benign prostatic hyperplasia. , 2015, The Canadian journal of urology.

[11]  H. Yagi,et al.  Clinical efficacy and tolerability of two Japanese traditional herbal medicines, Hachimi-jio-gan and Gosha-jinki-gan, for lower urinary tract symptoms with cold sensitivity , 2015, Journal of traditional and complementary medicine.

[12]  R. Capasso,et al.  Phytotherapy of Benign Prostatic Hyperplasia. A Minireview , 2014, Phytotherapy research : PTR.

[13]  Jun-Qing Zhang,et al.  Quantitative analysis of the major constituents in Chinese medicinal preparation SuoQuan formulae by ultra fast high performance liquid chromatography/quadrupole tandem mass spectrometry , 2013, Chemistry Central Journal.

[14]  John T. Wei,et al.  Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. , 2012, The New England journal of medicine.

[15]  P. Singam,et al.  Male sexual dysfunction in Asia. , 2011, Asian journal of andrology.

[16]  J. Jung,et al.  Correlation between Lower Urinary Tract Symptoms (LUTS) and sexual function in benign prostatic hyperplasia: impact of treatment of LUTS on sexual function. , 2009, The journal of sexual medicine.

[17]  Ruohua Chen,et al.  Superoxide radicals scavenging and xanthine oxidase inhibitory activity of magnesium lithospermate B from Salvia miltiorrhiza , 2009, Journal of enzyme inhibition and medicinal chemistry.

[18]  Tie-jun Li,et al.  Inhibitory effect of traditional Chinese medicine Zi-Shen Pill on benign prostatic hyperplasia in rats. , 2008, Journal of ethnopharmacology.

[19]  E. Crawford,et al.  The effect of α‐blocker and 5α‐reductase inhibitor intake on sexual health in men with lower urinary tract symptoms , 2007 .

[20]  J. Chiu,et al.  Effect of Epimedium brevicornum Maxim extract on elicitation of penile erection in the rat. , 2006, Urology.

[21]  T. Wilt,et al.  Phytotherapy for benign prostatic hyperplasia , 2000, Public Health Nutrition.

[22]  T. Wilt,et al.  Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. , 1998, JAMA.

[23]  M. Miner,et al.  Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function. , 2006, Clinical therapeutics.

[24]  Nickel Jc.  The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis. , 2006 .